Ipamorelin + Tesamorelin (10mg Blend) Dosage Protocol
GH-axis blend — Ipamorelin (ghrelin agonist) + Tesamorelin (GHRH analog) in one vial; Tesamorelin approved only for HIV lipodystrophy, this blend is not.
Fixed ratio: Ipamorelin 5 mg : Tesamorelin 5 mg — a 1:1 blend. Every withdrawal keeps that ratio, so the components cannot be dosed independently.
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers. Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →Mix & measure Ipamorelin + Tesamorelin · 10 mg
Tesamorelin + Ipamorelin Dosage Chart & Reconstitution Guide
One combined 10 mg blend vial — total-blend dosing, once daily, step by step
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
Reconstitute: Add 3.0 mL bacteriostatic water to the single 10 mg blend vial → ~3.33 mg/mL total peptide (3,333 mcg/mL).
Total daily dose: Weeks 1–4 at 330 mcg total, then Weeks 5–8 at 500 mcg total, once daily (or 5 days on, 2 off).
Easy measuring: At ~3.33 mg/mL, 1 unit ≈ 33 mcg total blend on a U-100 syringe — 330 mcg = 10 units, 500 mcg = 15 units.
50/50 split: Because both peptides share the vial, each total dose is roughly half Ipamorelin and half Tesamorelin (e.g. 330 mcg ≈ ~165 mcg Ipamorelin + ~165 mcg Tesamorelin).
Why Ipamorelin + Tesamorelin draws research interest
These are the directions researchers and the peptide community most often explore Ipamorelin + Tesamorelin for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.
GH & IGF-1 support
Studied for stimulating pulsatile growth hormone release, pairing a ghrelin agonist with a GHRH analog to raise IGF-1.
Visceral fat / lipolysis
Tesamorelin is FDA-approved to reduce visceral adipose tissue in HIV-associated lipodystrophy; this blend itself is not approved.
Body composition
Explored in research on lean mass and fat distribution through the GH/IGF-1 axis; investigational for this use, not approved.
Sleep & recovery
Investigated in preclinical work on slow-wave sleep and tissue repair tied to nocturnal growth hormone pulses.
Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.
Quickstart Highlights
This page covers a single 10 mg combined blend vial that holds Ipamorelin 5 mg + Tesamorelin 5 mg together. Tesamorelin is a stabilized GHRH(1–44) analog and Ipamorelin is a selective ghrelin / GHS-R1a agonist; pairing them is intended to stimulate the growth-hormone axis from two angles[1][4]. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy; Ipamorelin is not FDA-approved, and this blend and its dosing are not clinically validated. Presented for research and educational use only.
Add 3.0 mL bacteriostatic water to the single 10 mg blend vial → ~3.33 mg/mL total peptide (about 1.67 mg/mL of each).
330–1000 mcg total blend once daily (or 5 days on, 2 off) across an 8–12 week cycle; each dose splits roughly 50/50 between the two peptides.
At ~3.33 mg/mL, 1 unit ≈ 33 mcg total; 330 mcg ≈ 10 units and 500 mcg ≈ 15 units on a U-100 syringe.
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the solution.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.
Advanced / Aggressive Approach (2 mL = 5 mg/mL)
Reconstitute: Add 2.0 mL bacteriostatic water to the single 10 mg blend vial → 5 mg/mL total peptide (5,000 mcg/mL).
Total daily dose: Weeks 1–4 at 500 mcg total, then Weeks 5–8 at 1000 mcg total, once daily (or 5 days on, 2 off).
Easy measuring: At 5 mg/mL, 1 unit ≈ 50 mcg total blend on a U-100 syringe — 500 mcg = 10 units, 1000 mcg = 20 units.
50/50 split: Each total dose is about half of each peptide (e.g. 1000 mcg ≈ ~500 mcg Ipamorelin + ~500 mcg Tesamorelin).
Frequency: one subcutaneous injection each day (or a 5-on / 2-off schedule), over an 8–12 week cycle. The numbers below come from commonly cited reference schedules, not from approved human dosing of this blend.
Reconstitution Steps
Draw 3.0 mL (Standard) or 2.0 mL (Advanced) of bacteriostatic water into a sterile syringe.
Release it slowly down the vial's inner wall to limit foaming.
Swirl or roll the vial gently until both peptides fully dissolve — don't shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
With daily dosing at 500 mcg or higher, a single 10 mg blend vial may last only about 10–20 days — plan vial counts accordingly. Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptides.
Supplies Needed
Quantities below assume an 8–12 week course of once-daily injections from the combined 10 mg blend vial.
At higher daily doses one 10 mg blend vial may last only ~10–20 days, so plan multiple vials for a full cycle.
- Lower dose (~330 mcg/day): 1 vial ≈ 4 weeks
- 8 weeks: ~2–4 vials
- 12 weeks: ~3–6 vials
- Per injection: 1 syringe
- 8 weeks (once daily): ~56 syringes
- 12 weeks (once daily): ~84 syringes
Use 2–3 mL per 10 mg blend vial for reconstitution.
- 8 weeks: ~1–2 bottles
- 12 weeks: ~2 bottles
One for the vial stopper + one for the injection site each day.
- Per injection: 2 swabs
- 8 weeks (once daily): ~112 swabs → 1–2 boxes
Protocol Overview
A concise summary of the once-daily regimen for the combined Ipamorelin + Tesamorelin blend, drawn from commonly cited reference protocols.
- ▪Goal: Investigate dual growth-hormone-axis stimulation and body-composition effects — theoretical synergy that is not validated for this blend.
- ▪Schedule: Once daily, or 5 days on / 2 days off, for an 8–12 week cycle.
- ▪Dose Range: 330–1000 mcg total blend per day, raised gradually; each dose splits ~50/50 between the two peptides.
- ▪Reconstitution: 3.0 mL (~3.33 mg/mL) for the Standard approach or 2.0 mL (5 mg/mL) for the Advanced approach, per 10 mg blend vial.
- ▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C and do not freeze.
Dosing Protocol
A suggested daily titration approach for the combined blend, based on common reference doses.
- ▪Start: Begin at 330 mcg total once daily (Standard) to gauge tolerability.
- ▪Titrate: Step up to 500 mcg total around week 5; Advanced users run 500 → 1000 mcg.
- ▪Target: Reach 500–1000 mcg total daily by weeks 5–8, depending on approach.
- ▪Cycle Length: Typically 8–12 weeks, then assess or break before the next cycle.
- ▪Timing: Inject at a consistent time each day (evenings are common) and rotate injection sites.
Storage Instructions
Correct storage is what preserves both peptides' stability and activity.
- ▪Lyophilized: Hold the dry blend vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure.
- ▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 28 days; do not freeze the mixed solution.
- ▪Handling: Let a frozen vial warm to room temperature before opening so condensation won't form, and keep the solution clear of heat and direct light.
- ▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.
Important Notes
Practical points that keep daily administration safe and consistent.
- ▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward.
- ▪Volume tracking: The reconstitution volume sets the mcg per unit — track it carefully so your total-blend dose stays accurate.
- ▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy.
- ▪Monitoring: Because this drives the GH axis, watch glucose and (where relevant) IGF-1 at higher doses, and log observations across the cycle.
- ▪Regulatory note: Tesamorelin is FDA-approved only for HIV-associated lipodystrophy; Ipamorelin is not FDA-approved. Both are WADA-prohibited (class S2), and this blend is not approved for human use.
How This Works
Tesamorelin is a stabilized analog of growth-hormone-releasing hormone GHRH(1–44). It binds pituitary GHRH receptors to drive a pulsatile release of growth hormone, which in turn raises IGF-1; clinically it reduces visceral (deep abdominal) fat[1][2].
Ipamorelin works through a different door: it is a selective ghrelin / GHS-R1a agonist that triggers a clean GH pulse with little effect on cortisol or prolactin[4]. Because the two act on separate receptors, combining them is intended to stimulate the GH axis from two angles at once.
Important caveat: the idea that a GHRH analog plus a ghrelin agonist produce additive or synergistic GH output is a reasonable hypothesis, but it has not been validated for this specific blend or its dosing. Read the body-composition and “synergy” framing as theory, not established clinical fact.
Approval status (mixed): Tesamorelin (Egrifta / Egrifta SV) is FDA-approved, but only for HIV-associated lipodystrophy — body-composition, muscle and anti-aging use is off-label. Ipamorelin is not FDA-approved (a research chemical, 503A category 2). The blend is presented for research and educational purposes only.
Lifestyle Factors
Habits that may support outcomes alongside a GH-axis protocol.
- ▪Nutrition: Keep protein intake adequate and total calories aligned with your body-composition goal.
- ▪Activity & rest: Pair resistance training with real recovery time, since GH effects track with both stimulus and rest.
- ▪Sleep: Aim for 7–9 hours — the largest natural GH pulses occur during deep sleep.
- ▪Timing of carbs: Some protocols inject fasted or away from large carbohydrate meals, since elevated insulin can blunt the GH pulse.
Potential Benefits & Side Effects
What the framing of each peptide suggests; effects of the combined blend are not clinically established and individual results vary.
Potential Benefits
- ▪Visceral fat (Tesamorelin): In its approved HIV-lipodystrophy use, Tesamorelin reduces deep abdominal fat and raises IGF-1.
- ▪GH pulse (Ipamorelin): A clean, selective GH release is the rationale for stacking it with a GHRH analog.
- ▪Theoretical synergy: Dual-axis stimulation is proposed to support lean mass, recovery and body composition — not validated for this blend.
- ▪Note on humans: The combined blend has no completed efficacy trials; treat body-comp claims as hypotheses.
Common Side Effects
- ▪Injection-site reactions: Mild redness, tenderness or soreness can occur; rotating sites helps.
- ▪Fluid retention & GI: GH-axis stimulation can cause water retention, joint aches or mild nausea/GI discomfort.
- ▪Glucose / IGF-1: Higher GH output can affect insulin sensitivity; monitor glucose and IGF-1 at higher doses.
- ▪Sport restriction: Both peptides are WADA-prohibited (class S2) for athletes.
Injection Technique
General subcutaneous technique, following established clinical best-practice guidance[5][6].
Pre-Injection Preparation
- ▪Wash your hands well with soap and water.
- ▪Wipe the vial stopper with an alcohol swab and let it air-dry.
- ▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[6].
- ▪Draw the intended total-blend dose, then check for air bubbles and push any out.
Injection Procedure
- ▪Pinch a skinfold at the chosen site between thumb and forefinger.
- ▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[5].
- ▪Skip aspiration for subcutaneous shots — it isn't needed[5].
- ▪Press the plunger slowly and steadily until it's fully down.
- ▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
Post-Injection Care
- ▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
- ▪Return the reconstituted vial to the fridge right away.
- ▪Rotate the injection site each day to prevent irritation and lipohypertrophy.
- ▪Watch the site for excess redness, swelling, or signs of infection.
Recommended Source
For high-purity research peptides, we point researchers to Prime Lab Peptides.
Why Prime Lab Peptides?
- ▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.
- ▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
- ▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
- ▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
- ▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
References
- 1
FDA Label — Egrifta (tesamorelin)Prescribing information for tesamorelin, FDA-approved only for reduction of excess abdominal fat in HIV-associated lipodystrophy.
- 2
New England Journal of Medicine (PubMed)Randomized trials of tesamorelin showing reduced visceral adipose tissue and raised IGF-1 in HIV-associated lipodystrophy.
- 3
Clinical Infectious Diseases (PubMed)Long-term tesamorelin data on visceral fat, IGF-1 and metabolic safety.
- 4
European Journal of Endocrinology (PubMed)Ipamorelin characterized as a selective ghrelin / GHS-R1a agonist producing a GH pulse with minimal cortisol or prolactin effect.
- 5
CDC — Injection Safety / Best PracticesGuidance on safe injection technique, needle angle and disposal of sharps.
- 6
WHO Best Practices for InjectionsSubcutaneous injection technique, site preparation and rotation guidance.
- 7
WADA Prohibited List (S2)Growth hormone secretagogues including GHRH analogs and ghrelin / GHS-R1a agonists are prohibited at all times under class S2.
Ipamorelin + Tesamorelin — frequently asked questions
How do I reconstitute a 10 mg vial of Ipamorelin + Tesamorelin?
Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units.
How much bacteriostatic water should I add to Ipamorelin + Tesamorelin?
There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units.
What do the "units" on an insulin syringe mean?
On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand.
How should I store Ipamorelin + Tesamorelin after mixing?
Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product.
How many doses does a 10 mg vial of Ipamorelin + Tesamorelin provide?
Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose.
Is Ipamorelin + Tesamorelin approved for human use?
No. Ipamorelin + Tesamorelin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.
New protocols & dosing updates
Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.